Denali Capital Acquisition Corp. (DECA) to Combine with Longevity Biomedical in $236M Deal
Denali Capital (NASDAQ:DECA) has entered into a definitive agreement to combine with biopharmaceutical firm Longevity at an equity value of $236.2 million. Bothell, Washington-based Longevity is building a platform to consolidate a number of clinical-stage therapies, beginning with treatment candidates aiming to improve outcomes of certain vascular conditions as well as replace lost tissue. TheRead More
To access this post, you must purchase 1 - User: Monthly Plan.